The regulation of clotting factors

Critical Reviews in Eukaryotic Gene Expression

Volumn 7, Issue 3, 1997, Pages 241-280

  Kalafatis, Michael ^a   Egan, Jack O ^a   Van 't Veer, Cornelis ^a   Cawthern, Kevin M ^a   Mann, Kenneth G ^a  

^a UNIVERSITY OF VERMONT   (United States)

Author keywords

APC; Cofactors; Factor Va; Factor VIIIa; Inhibitors; Membrane surface; Proteolysis

Indexed keywords

ACTIVATED PROTEIN C; ANTICOAGULANT AGENT; ANTITHROMBIN III; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 5A; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 8A; BLOOD CLOTTING FACTOR 9A; ENZYME PRECURSOR; FIBRIN; PROCOAGULANT; PROTHROMBIN COMPLEX; SERINE PROTEINASE INHIBITOR; THROMBIN; THROMBOMODULIN; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR;

BLEEDING; BLOOD CLOTTING; BLOOD VESSEL INJURY; CELL SURFACE; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME ACTIVE SITE; ENZYME ACTIVITY; FIBRIN CLOT; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEINASE INHIBITION; REVIEW; STOICHIOMETRY; THROMBOSIS;

EID: 0031417262     PISSN: 10454403     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevEukarGeneExpr.v7.i3.40     Document Type: Review

References (317)

1. 2+ dependant protein kinase (protein kinase C). Biochem Biophys Res Comm 176:1123-1129.
2. Ahmad SS, Rawala-Sheikh R, Ashby B, Walsh PN (1989): Platelet receptor-mediated factor X activation by factor IXa. High-affinity factor IXa receptors induced by factor VIII are deficient on platelets in Scott syndrome. J Clin Invest 94:824-828.
3. Almus FE, Rao LVM, Rappaport SI (1989): Functional properties of factor VIIa/tissue factor formed with purified tissue factor and with tissue factor expressed on cultured endothelial cells. Thrombosis Haemostasis 62:1067-1073.
4. Anson DS, Choo KH, Rees DJG (1984): The gene structure of human anti-haemophilic factor IX. EMBO J 3:1053-1060.
5. Asakai R, Davie EW, Chung DW (1987): Organization of the gene for human factor XI. Biochemistry 26:7221-7228.
6. Bach R, Konigsberg W, Nemerson Y, (1988): Human tissue factor contains thioester-linked palmitate and stearate on the cytoplasmic half cysteine. Biochemistry 27:4227-4231.
7. Bajaj MS, Kuppuswamy MN, Saito H, Spitzer SG, Bajaj SP (1990): Cultured normal human hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor: evidence that endothelium is the principal site of its synthesis. Proc Natl Acad Sci USA 87:8869-8873.
8. Bajaj SP, Rapaport SI, Brown SF (1981): Isolation and characterization of human factor VII. J Biol Chem 256:253-259.
9. Bajzar L, Nesheim ME (1993): The effect of activated protein C on fibrinolysis in cell-free plasma can be attributed specifically to attenuation of prothrombin activation. J Biol Chem 268:8608-8616.
10. Bajzar L, Manuel R, Nesheim ME (1995): Purification and characterization of TAFI, a thrombin-activatable fibrinolysis inhibitor. J Biol Chem 270:14477-14484.
11. LEIDEN. J Biol Chem 271:22949-22952.
12. Baker ME, French FS, Joseph DR (1987): Vitamin K-dependent protein S is similar to rat androgen binding protein. Biochemistry 243:293-296.
13. Bancroft JD, McDowell SA, Degen SJ (1992): The human prothrombin gene: transcriptional regulation in HepG2 cells. Biochemistry 31:12469-12476.
14. Barlati S, Paracini F, Bellotti D, DePetro G (1991): Tyrosine phosphorylation of human urokinase-type plasminogen activator. FEBS 281:137-140.
15. Baumgartner-Parzer SM, Wagner L, Petterman M, Grillari J, Gessl A, Waldhäusl W (1995): High-glucose-triggered apoptosis in cultured endothelial cells. Diabetes 44:1323-1327.
16. Beleznay Z, Zachowski A, Devaux PF, Navazo MP, Ott P (1993): ATP-dependent aminophospholipid translocation in erythrocyte vesicles: Stoichiometry of transport. Biochemistry 32:3146-3152.
17. Bennett MR, Gibson DF, Schwartz SM, Tait JF (1995): Binding and phagocytosis of apoptotic vascular smooth muscle cells is mediated in part by exposure of phosphatidylserine. Circ Res 77:1136-1142.
18. Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH (1994): Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369:64-67.
19. Bevers EM, Comfurius P, VanRijn JLML, Hemker HC, Zwaal RFA (1982): Generation of prothrombin-converting activity and the exposure of phosphatidylserine at the outer surface of platelets. Eur J Biochem 122:429-436.
20. Bevers EM, Comfurius P, Zwaal RFA (1983): Changes in membrane phospholipid distribution during platelet activation. Biochem Biophys Acta 736:57-66.
21. Bevers EM, Tilly RH, Senden JM, Comfurius P, Zwaal RFA (1989): Exposure of endogenous phosphatidylserine at the outer surface of stimulated platelets is reversed by restoration of aminophospholipid tranlocase activity. Biochemistry 28:2382-2387.
22. 2+-induced microvesiculation and deficient expression of procoagulant activity in erythrocytes from a patient with a bleeding disorder: a study of the red blood cells of Scott syndrome. Blood 79:380-388.
23. Bevilacqua MP, Pober JS, Majeau GR, Cotran RS, Gimbrone MA (1984): Interleukin 1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells. J Exp Med 160:618-623.
24. Bevilacqua MP, Pober JS, Majeau GR, Fiers W, Cotran RS, Gimbrone MA (1986): Recombinant tumor necrosis factor induces procoagulant activity in cultured human endothelium. Proc Natl Acad Sci USA 83:4533-4537.
25. Bitbol M, Fellman P, Zachowski A, Devaux PF (1987) Ion regulation of phosphatidylserine and phosphatidylethanolamine outside-inside translocation in human erythrocytes. Biochim Biophys Acta 904:268-282.
26. Blombäck B, Carlson LA, Franzen S, Zetterqvist E (1966): Turnover of 131-I-labeled fibrinogen in man. Studies in normal subjects, in congenital coagulation factor deficiency states in liver cirrhosis, in polycythemia vera and in epidermolysis bullosa. Acta Med Scand 179:557-574.
27. Blombäck B, Blombäck M, Henschen A, Hessel B, Iwanaka S, Woods KR (1968): N-terminal disulfide knot of human fibrinogen. Nature 218:130-134.
28. Bolton-Maggs, PHB (1996): Factor XI deficiency. Ballière's Clin Hematol 9:355-368.
29. Bombeli T, Karsan A, Tait JF, Harlan JM (1997): Apoptotic vascular endothelial cells become procoagulant. Blood 89:2429-2442.
30. Branson HE, Katz J, Marble R, Griffin JH (1983): Inherited protein C deficiency and coumarin-responsive chronic relapsing purpura fulminans in a newborn infant. Lancet 2:1165-1168.
31. Bottenus RE, Ichinose A, Davie EW (1990): Nucleotide sequence of the gene for the b subunit of human factor XIII. Biochemistry 29:11195-11209.
32. Bouma BN, Griffin JH (1977): Human blood coagulation Factor XI: purification, properties, and mechanism of activation by activated Factor XII. J Biol Chem 252:64327-66437.
33. Chapel Hill by human factor XIa. J Clin Invest 68:1420-1426.
34. Broze GJ Jr., Lange GW, Duffin KL, MacPhail L (1994): Heterogeneity of plasma tissue factor pathway inhibitor. Blood Coag Fibrin 5:551-559.
35. Broze, GJ Jr. (1995): Tissue factor pathway inhibitor and the revised theory of coagulation. Ann Rev Med 46:103-112.
36. Broze GJ Jr., Higuchi D (1996): Coagulation-dependent inhibition of fibrinolysis: role of carboxypeptidase-U and the premature lysis of clots from hemophilic plasma. Blood 88:3815-3823.
37. Brox JH, Østerud B, Bjørklid E, Fenton JW II (1984): Production and availability of thromboplastin in endothelial cells: the effects of thrombin, endotoxin, and platelets. Br J Haematol 57:239-246.
38. Brunnée T, LaPorta C, Reddigari SR, Salerno VM, Kaplan AP, Silverberg M (1993): Activation of factor XI in plasma is dependent on factor XII. Blood 81:580-586.
39. Cash JD, Gader MA, DaCosta J (1974): The release of plasminogen activator and factor VIII lysine vasopressin, arginine vasopressin, I-desamino-8-d-arginine vasopressin, angiotensin and oxytocin in man. Br J Haematol 27:363-364
40. Casu B, Oreste P, Torri G, Zoppetti G (1981): The structure of heparin oligosaccharide fragments with high anti-(factor Xa) activity containing the minimal antithrombin III-binding sequence. Biochem J 197:599-609.
41. Cerveny TJ, Fass DN, Mann KG (1984): Synthesis of coagulation Factor V by cultured aortic endothelium. Blood 63:1467-1474.
42. Chen R, Doolittle RF (1971): Cross-linking sites in human and bovine fibrin. Biochemistry 10:4487-4491.
43. Chiu HC, Schick P, Colman R (1985): Biosynthesis of Factor V in isolated guinea pig megakaryocytes. J Clin Invest 75:339-346.
44. Chow BK, Ting V, Tufaro F, MacGillivray RT (1991): Characterization of a novel liver-specific enhancer in the human prothrombin gene. J Biol Chem 266:18927-18933.
45. Chung DW, Harris JE, Davie EW (1990): Nucleotide sequences of the three genes coding for human fibrinogen. Adv Exp Med Biol 281:39-48.
46. Clouse LH and Comp PC (1986): The regulation of hemostasis: the protein C system. New Engl J Med 314:1298-1304.
47. Colman RW, Bagdasarian A, Talamo RC, Scott RF, Seavey M, Guimaraes JA, Pierce JV, Kaplan AP (1975): Williams trait. Human kininogen deficiency with diminished levels of plasminogen proactivator and prekallikrein associated with abnormalities of the Hageman factor-dependent pathways. J Clin Invest 56:1650-1662.
48. Colucci M, Balconi G, Lorenzet R, Pietra A, Locati D, Donati MB, Semeraro N (1983): Cultured human endothelial cells generate tissue factor in response to endotoxin. J Clin Invest 71:1893-1896.
49. Comp PC, Nixon RR, Cooper MR, Esmon CT (1984): Familial protein S deficiency is associated with recurrent thrombosis. J Clin Invest 74:2082-2088.
50. Connor J, Schroit AJ (1987): Determination of lipid asymmetry in human red cells by resonance energy transfer. Biochemistry 26:5099-5105.
51. Connor J, Pak CH, Zwaal PF, Schroit AJ (1992): Bidirectional transbilayer movement of phospholipid analogs in human red blood cells. J Biol Chem 267:19412-19417.
52. Cooksey MW, Perry CB, Raper AB (1966): Epsilonaminocaproic acid therapy for dental extractions in haemophiliacs. Br Med J 2:1633-1634.
53. Creasey AA, Chang ACK, Feigen L, Wun TC, Taylor FB, Jr., Hinshaw LB, (1993): Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest 91:2850-2860.
54. Cripe LD, Moore KD Kane WH (1992): Structure of the gene for human coagulation factor V. Biochemistry 31:3777-3785.
55. Cui J, O'Shea KS, Purkayastha A, Saunders TL, Ginsburg D (1996): Fatal haemorrhage and incomplete block to embryogenesis in mice lacking coagulation factor V. Nature 384:66-68.
56. 2+-ATPase inhibitors. Biochemistry 34:11625-11634.
57. Dahlbäck B (1986): Inhibition of protein Ca cofactor function of human and bovine protein S by C4b-binding protein. J Biol Chem 261:12022-12027.
58. Dahlbäck B, Carlsson M, Svensson PJ (1993): Familial thrombophilia due to a previously unrecognized mechanism by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 90:1004-1008.
59. Daleke DL, Huestis WH (1985): Incorporation and translocation of aminophospholipids in human erythrocytes. Biochemistry 24:5406-5416.
60. Davie EW, Ratnoff OD (1964): Waterfall sequence for intrinsic blood clotting. Science 145:1310-1312.
61. Degen SJ, MacGillivray RTA, Davie EW (1983): Characterization of the complementary deoxyribonucleic acid and gene coding for human prothrombin. Biochemistry 22:2087-2097.
62. Degen SJ, Davie EW (1987). Nucleotide sequence of the gene for human prothrombin. Biochemistry 26:6165-6177.
63. DiScipio RG, Hermodson MA, Yates SG, Davie EW (1977): A comparison of human prothrombin, Factor IX (Christmas factor), Factor X (Stuart factor), and protein S. Biochemistry 16:698-706.
64. 2+ ion-mediated binding of prothrombin fragment 1 to phopspholipid vesicles and a molecular model for its association with phospholipids. J Biol Chem 254:5027-5040.
65. Doyle MF, Mann KG (1990): Multiple active forms of thrombin. J Biol Chem 265:10693-10701.
66. Drake TA, Morrissey JH, Edgington TS (1989a): Selective cellular expression of tissue factor in human tissues: implications for disorders of hemostasis and thrombosis. Am J Pathol 134:1087-1097.
67. Drake TA, Ruf W, Morrissey JH, Edgington TS (1989b): Functional tissue factor is entirely cell surface expressed on lipopolysaccharide-stimulated human blood monocytes and a constitutively tissue factor producing neoplastic cell line. J Cell Biol 109:389-395.
68. Elion J, Downing MR, Butkowski RJ, Mann KG (1977): Structure of human thrombin: comparison with other serine proteases, pp 97-112. In Lundblad RL, Fenton JW, Mann KG (eds.): The Chemistry and Biology of Thrombin. Ann Arbor, MI: Ann Arbor Science Press.
69. Erdmann D, Heim J (1995): Orphan nuclear receptor HNF-4 binds to the human coagulation factor VII promoter. J Biol Chem 270:22988-22996.
70. Esmon, CT (1987): The regulation of natural anticoagulant pathways. Science 235:1348-1352.
71. Fay PJ, Haidaris PJ, Smudzin TM (1991a): Human factor VIIIa subunit structure. Reconstitution of factor VIIIa from the isolated A1/A3-C1-C2 dimer and A2 subunit. J Biol Chem 266:8957-8962.
72. Fay PJ, Smudzin TM, Walker FJ (1991b): Activated protein C-catalyzed inactivation of human factor VIII and factor VIIIa: identification of cleavage sites and correlation of proteolysis with cofactor activity. J Biol Chem 266:20139-20145.
73. Fay PJ, Smudzin TM (1992): Characterization of the interaction of the A2 subunit and AI/A3-C1-C2 dimer in human factor VIII. J Biol Chem 267:13246-13250.
74. Figueiredo MS, Brownlee GG (1995): cis-acting elements and transcription factors involved in the promoter activity of the human factor VIII gene. J Biol Chem 270:11828-11838.
75. Forsberg P-O, Martin SC, Nilsson B, Ekman P, Nilsson UR, Engstrom L (1990): In vitro phosphorylation of human complement factor C3 by protein kinase A and protein kinase C. J Biol Chem 265:2941-2946.
76. Foster DC, Yoshitake S, Davie EW (1985): The nucleotide sequence of the gene for human protein C. Proc Natl Acad Sci USA 82:4673-4677
77. Franck PFH, Bevers EM, Lubin BH, Comfurius P, Chiu DT-Y, OpDenKamp JAF, Van Deenen LLM, Roelofsen B (1985): Uncoupling of the membrane skeleton from the lipid bilayer: the cause of accelerated flip-flop leading to enhanced procoagulant activity of sickled cells. J Clin Invest 75:183-190.
78. 2 (Stuart Factor). Isolation and characterization. Biochemistry 11:4882-4891.
79. Fujikawa K, Chung DW, Hendrickson LE, Davie EW (1986): Amino acid sequence of human Factor XI: a blood coagulation factor with four tandem repeats that are highly homologous with plasma prekallikrein. Biochemistry 25:2417-2424.
80. Gailani D, Broze GJ, Jr. (1991): Factor XI activation in a revised model of blood coagulation. Science 253:909-912.
81. Garlund B, Hessel B, Marguerie G, Murano G, Blombäck B (1977): Primary structure of human fibrinogen. Eur J Biochem 77:595-610.
82. Gershagen S, Lundwall A, Fernlund P (1989): Characterization of the human sex hormone binding globulin (SHBG) gene and demonstration of two transcripts in both liver and testis. Nucl Acids Res 17:9245-9258.
83. Gitschier J, Wood WI, Goralka TM, Wion KL, Chen EY, Eaton DH, Vehar GA, Capon DJ, Lawn RM (1984): Characterization of the human factor VIII gene. Nature 312:326-330.
84. Griffin JH, Evatt B, Zimmerman TS, Kleiss AJ, Wideman C (1981): Deficiency of protein C in congenital thrombotic disease. J Clin Invest 68:1370-1373.
85. Griffin JH, Mosher DF, Zimmerman TS, Kleiss AJ (1982): Protein C, an antithrombotic protein, is reduced in hospitalized patients with intravascular coagulation. Blood 60:261-264.
86. Griffin JH, Evatt B, Wideman C, Fernandez JA (1993): Anticoagulant protein C pathway defective in the majority of thrombophilic patients. Blood 82:1989-1993.
87. Griffith MJ, Breitkreutz L, Trapp H, Briet E, Noyes CM, Lundblad RL, Roberts HR (1985): Characterization of the clotting activities of structurally different forms of activated factor IX. J Clin Invest 75:4-10.
88. Guasch MD, Plana M, Pena JM, Itarte E (1986): Phosphorylation of fibrinogen by casein kinase 2. Biochem J 234:523-526.
89. Hackeng TM, van 't Veer C, Meijers JCM, Bouma BN (1994). Human protein S inhibits prothrombinase complex activity on endothelial cells and platelets via direct interactions with factors Va and Xa. J Biol Chem 269:21051-21058.
90. Hagen FS, Gray CL, O'Hara P, Grant FJ, Saari GC, Woodbury RG, Hart CE, Insley M, Kisiel W, Kurachi K, Davie EW (1986): Characterization of a cDNA coding for human factor VII. Proc Natl Acad Sci USA 83:2412-2416.
91. Haley PE, Doyle MF, Mann KG (1989): The activation of bovine protein C by factor Xa. J Biol Chem 264:16303-16310.
92. Hantgan R, Fowler W, Erickson H, Hermans J (1980): Fibrin assembly: a comparison of electron microscopic and light scattering results. Thromb Haemost 44:119-124.
93. Hathaway WE, Belhasen LP, Hathaway HS (1965): Evidence for a new plasma thromboplastin factor. I. Case report, coagulation studies and physicochemical properties. Blood 26:521-532.
94. Heeb MJ, Mesters RM, Tans G, Rosing J, Griffin JH (1993): Binding of protein S to factor Va associated with inhibition of prothrombinase that is independent of activated protein C. J Biol Chem 268:2872-2877.
95. Heeb MJ, Rosing J, Bakker HM, Fernandez JA, Tans G, Griffin JH (1994): Protein S binds to and inhibits factor Xa. Proc Natl Acad Sci USA 91:2728-2732.
96. Heldebrant CM, Butkowski RJ, Bajaj SP, Mann KG (1973): The activation of prothrombin. II. Partial reactions, physical and chemical characterization of the intermediates of activation. J Biol Chem 248:7149-7163.
97. Heldin P (1987): Phosphorylation of human fibrinogen with casein kinase TS and characterization of phosphorylated sites. Arch Biochem Biophys 257:269-275.
98. Hillery CA, Smyth SS, Parise LV (1991): Phosphorylation of human platelet glycoprotein IIIa (GPIIIa). J Biol Chem 266:14663-14669.
99. Higgins DL, Mann KG (1983): The interaction of bovine factor V and factor V-derived peptides with phospholipid vesicles. J Biol Chem 258:6503-6508.
100. Hortin GL (1993): Sulfation of tyrosine residues in coagulation factor V. Blood 76:946-952.
101. Hoskins J, Norman DK, Beckmann RJ, Long GL (1987): Cloning and characterization of human liver cDNA encoding a protein S precursor. Proc Natl Acad Sci USA 84:349-353.
102. Hoyer LW (1987): Molecular pathology and immunology of factor VIII (Hemophilia A and factor VIII inhibitors). Hum Pathol 18:153-161.
103. Hovig T, Dodds WJ, Rowsell HC, Mustard JF (1968): The transformation of haemostatic platelet plugs in normal and factor IX-deficient dogs. Am J Pathol 53:355-374.
104. Huang Z, Wun T, Broze GJ, Jr (1993): Kinetics of factor Xa inhibition by tissue factor pathway inhibitor. J Biol Chem 268:26950-26955.
105. Huang ZF, Broze GJ, Jr. (1997): Consequences of tissue factor pathway inhibitor gene-disruption in mice. Thrombosis Haemostasis 78:699-704 (Abstr.)
106. Hung HL, High KA (1996): Liver-enriched transcription factor HNF-4 and ubiquitous factor NF-Y are critical for expression of blood coagualtion factor X. J Biol Chem 271:2323-2331.
107. Ichinose A, McMullen B, Fujikawa K (1986): Amino acid sequence of the b subunit of human factor XIII, a protein composed of 10 repetitive segments. Biochemistry 25:4633-4638.
108. Ichinose A (1994). The physiology and biochemistry of factor XIII. In: Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD (eds.), Haemostasis and Thrombosis. New York: Churchill Livingstone, pp. 531-546.
109. Ichinose A, Davie EW (1988): Characterization of the gene for the a subunit of human factor XIII (plasma transglutaminase), a blood coagulation factor. Proc Natl Acad Sci USA 85:5829-5833.
110. Itarte E, Plana M, Guasch MD, Martos, C (1983): Phosphorylation of fibrinogen by casein kinase 1. Biochem Biophys Res Comm 117:631-636.
111. Jackman RW, Beeler DL, van de Walter L, Rosenberg RD (1986): Characterization of a thrombomodulin cDNA reveals structural similarity to the low-density lipoprotein receptor. Proc Natl Acad Sci USA 83:8834-8838.
112. Jackman RW, Beeler DL, Fritze L, Soff G, Rosenberg RD (1987): Human thrombomodulin gene is intron depleted: nucleic acid sequence of the cDNA and gene predict protein structure and suggest sites of regulatory control. Proc Natl Acad Sci USA 84:26425-26429.
113. Jenny RJ, Pittman DD, Toole JJ, Kriz RW, Aldape RA, Hewick RM, Kaufman RJ, Mann KG (1987): Complete cDNA and derived amino acid sequence of human factor V. Proc Natl Acad Sci USA 84:4846-4850.
114. Jesty J (1978): The inhibition of activated bovine coagulation factors X and VII by antithrombin III. Arch Biochem Biophys 185:165-173.
115. Jesty J, Nemerson Y (1979): The activation of bovine coagulation factor X. Methods Enzymol 45:95-107.
116. Julien M, Tournier JF, Tocanne JF (1995): Basic fibroblast growth factor modulates the aminophospholipid translocase present in the plasma membrane of bovine aortic endothelial cells. Eur J Biochem 230:287-297.
117. Kalafatis M, Rand MD, Jenny RJ, Ehrlich YH, Mann KG (1993): Phosphorylation of factor Va and factor VIIIa by activated platelets. Blood 81:704-719.
118. Kalafatis M, Swords NA, Rand MD, Mann KG (1994a): Membrane-dependent reactions in blood coagulation: role of the vitamin K-dependent enzyme complexes. Biochim Biophys Acta 1227:113-129.
119. Kalafatis M, Rand MD, Mann KG (1994b): The mechanism of inactivation of human factor V and human factor Va by activated protein C. J Biol Chem 269:31869-31880.
120. R506Q. J Biol Chem 270:4053-4057.
121. Kalafatis M, Haley PE, Lu D, Bertina RM, Long GL, Mann KG (1996): Proteolytic events that regulate factor V activity in whole plasma from normal and activated protein C (APC)-resistant individuals during clotting: an insight into the APC-resistance assay. Blood 87:4695-4707.
122. Kalafatis M, Mann KG, 1993. Role of the membrane in the inactivation of factor Va by activated protein C. J Biol Chem 268:27246-27257
123. Kalafatis M (1996): The effect of factor Va phosphorylation on cofactor inactivation. Circulation (suppl. 1):1270 (Abstr.).
124. Kane WH, Ichinose A, Hagen FS, Davie EW (1987): Cloning of cDNAs coding for the heavy chain region and connecting region of human Factor V, a blood coagulation factor with four types of internal repeats. Biochemistry 26:6508-6514.
125. Kane WH, Davie EW (1988): Blood coagulation factors V and VIII: structural and functional similariities and their relationship to hemorrhagic and thrombotic disorders. Blood 71:539-555.
126. Kane WH, Majerus PW (1981): Purification and characterization of human coagulation factor V. J Biol Chem 256:1002-1007.
127. Kato A, Asaki R, Davie EW, Aoki N (1989): Factor XI gene (F11) is located on the distal end of the long arm of chromosome 4. Cytogenet Cell Genet 52:77-78.
128. Kisiel W, Fujikawa K, Davie EW (1977): Activation of bovine factor VII (proconvertin) by factor XIIa (activated Hageman factor). Biochemistry 16:4189-4194.
129. Kisiel W (1979). Human plasma protein C. J Clin Invest 64:761-769.
130. Kisiel W, Davie EW (1975): Isolation and characterization of bovine factor VII. Biochemistry 14:4928-4934.
131. Kisiel W, Davie EW (1981): Protein C. Methods Enzymol 80:320-332.
132. Kisiel W, Hanahan DJ (1973): Purification and characterization of human factor II. Biochem Biophys Acta 304:103-113.
133. Kitchens CS (1991): Factor XI: a review of its biochemistry and deficiency. Semin Thromb Hemost. 13:86-94.
134. Kobayashi I (1979): Treatment of hemophilia A and von Willebrand's disease with an intranasal dripping of DDAVP. Thromb Res 16:775-779
135. Koedam JA, Meijers JC, Sixma JJ, Bouma BN (1988): Inactivation of human factor VIII by activated protein C. Cofactor activity of protein S and protective effect of von Willebrand factor. J Clin Invest 82:1236-1243.
136. Koppelman SJ, Hackeng TM, Sixma JJ, Bouma BN (1995): Inhibition of the intrinsic factor X activating complex by protein S: evidence for a specific binding of protein S to factor VIII. Blood 86:1062-1071.
137. Kork-Grodzieki B, Tauber-Finkelstein M, Shaltiel S (1988): Platelet stimulation releases a cAMP-dependent protein kinase that specifically phosphorylates a plasma protein. Proc Natl Acad. Sci USA 85:7541-7545.
138. Koster T, Rosendaal FR, de Ronde H, Brie TE, Vandenbroucke JP, Bertina RM (1993): Venous thrombosis due to poor anticoagulant response to activated protein C: leiden thrombophilia study. Lancet 342:1503-1506.
139. Krishnaswamy S, Church WR, Nesheim ME, Mann KG, (1987): Activation of human prothrombin by human prothrombinase: influence of factor Va on the reaction mechanism. J Biol Chem 262:3291-3299.
140. Krishnaswamy S, Mann KG (1988): The binding of factor Va to phospholipid vesicles. J Biol Chem 263:5714-5723.
141. Krust B, Galabru J, Hovanessian AG (1983): Phosphorylation of the a-chain of fibrinogen by a platelet kinase activity enhanced by interferon. Biochem Biophys Res Comm 117:350-357.
142. Kurachi K, Fujikawa K, Schmer G, Davie EW (1976): Inhibition of bovine factor IXa and factor Xa by antithrombin III. Biochemistry 15:373-377.
143. Kurachi K, Davie EW (1982): Isolation and characterization of a cDNA coding for human factor IX. Proc Natl Acad Sci USA 79:6461-6464.
144. Lawson JH, Kalafatis M, Stram S, Mann KG (1994): A model for the tissue factor pathway to thrombin. I. An empirical study. J Biol Chem 269:23357-23366.
145. Lawson JH, Butenas S, Mann KG (1992): The evaluation of complex-dependent alterations in human factor VIIa. J Biol Chem 267:4834-4843.
146. Lawson JH, Butenas S, Ribarik N, Mann KG (1993): Complex-dependent inhibition of factor VIIa by antithrombin III and heparin. J Biol Chem 268:767-770.
147. Lawson JH, Mann KG (1991): Cooperative activation of human factor IX by the human extrinsic pathway of blood coagulation. J Biol Chem 266:11317-11327.
148. 1680 of human blood coagulation factor VIII is essential for the interaction of factor VIII with von Willebrand factor. J Biol Chem 266:740-746.
149. Leytus SP, Chung DW, Kisiel W, Kurachi K, Davie EW (1984): Characterization of a cDNA coding for human factor X. Proc Natl Acad Sci USA 81:3699-3702.
150. Lindhout T, Willems G, Blezer R, Hemker HC (1997): Kinetics of inhibition of human factor Xa by full length and truncated recombinant tissue factor pathway inhibitor. Biochem J 297:131-136.
151. Lollar P, Hill-Eubanks DC, Parker CG (1988): Association of the factor VIII light chain with von Willebrand factor. J Biol Chem 263:10451-10455.
152. Lollar P, Parker CG (1987a): Subunit structure of thrombin-activated porcine factor VIII. Biochemistry 28:666-674.
153. Lollar P, Parker CG, (1987b): Stoichiometry of the porcine factor VIII-von Willebrand factor association. J Biol Chem 262:17572-17576.
154. Lollar P, Parker C (1990): pH-dependent denaturation of thrombin-activated porcine factor VIII. J Biol Chem 265:1688-1692.
155. Long GL, Belagaje RM, Macgillivray TA (1984): Cloning and sequencing of liver cDNA coding for bovine protein C. Proc Natl Acad Sci USA 81:5653-5656.
156. Lu D, Kalafatis M, Mann KG, Long GL (1996): Comparison of activated protein C/protein S-mediated activation of human factor VIII and factor V. Blood 87:4708-4717.
157. Lundblad RL, Kingdon HS, Mann KG (1976): Thrombin. In: Lorand L (ed.): "Methods in Enzymology, Proteolytic Enzymes, Part B." New York: Academic Press, pp. 156-176.
158. Lupu C, Calb M, Ionescu M, Lupu F (1993): Enhanced prothrombin and intrinsic factor X activation on blood platelets from diabetic patients. Thromb Hemost 70:579-583.
159. Lyberg T, Galdal KS, Evensen SA, Prydz H (1983): Cellular cooperation in endothelial cell thromboplastin synthesis. Br J Haematol 53:85-95.
160. MacFarlane RG (1964): An enzyme cascade in the blood clotting mechanism and its function as a biochemical amplifier. Nature 202:498-499.
161. MacGillivray RTA, Davie EW (1984): Characterization of bovine prothrombin mRNA and its translation product. Biochemistry 23:1626-1634.
162. McGuire EA, Peacock ME, Inhorn RC, Siegel NR, Tollefsen DM (1988): Phosphorylation of vitronectin by a protein kinase in human plasma. J Biol Chem 263:1942-1945.
163. Mackman N, Morrissey JH, Fowler B, Edgington TS (1989): Complete sequence of the human tissue factor gene, a highly regulated cellular receptor that initiates the coagulation protease cascade. Biochemistry 28:1755-1762.
164. Mackman N, Fowler BJ, Edgington TS, Morrissey JH (1990): Functional analysis of the human tissue factor promoter and induction by serum. Proc Natl Acad Sci USA 87:2254-2258.
165. Mackman N, Brand K, Edgington TS (1991): Lipopolysaccharide-mediated transcriptional activation of the human tissue factor gene in THP-1 monocytic cells requires both activator protein 1 and nuclear factor kb binding sites. J Exp Med 174:1517-1526.
166. Mackman N (1995): Regulation of the tissue factor gene. FASEB J 9:883-889.
167. Mann KG, Nesheim ME, Tracy PB (1981): Molecular weight of undegraded plasma factor V. Biochemistry 20:28-33.
168. Mann KG, Jenny RJ, Krishnaswamy S (1988): Cofactor proteins in the assembly and expression of blood clotting enzyme complexes. Ann Rev Biochem 57:915-956.
169. Mann KG, Krishnaswamy S, Lawson JH (1992): Surface-dependent hemostasis. Semin Hematol 29:213-226.
170. Mann KG, Nesheim ME, Church WR, Haley P, Krishnaswamy S (1990): Surface-dependent reaction of the vitamin K-dependent enzyme complexes. Blood 76:1-16.
171. Mann KG, Hockin MF, Begin KJ, Kalafatis M (1997): Activated protein C cleavage of factor Va leads to dissociation of the A2 domain. J Biol Chem 272: in press.
172. Mannucci PM, Åberg M, Nilsson IM, Robertson B (1975): The mechanism of plasminogen activator and factor VIII increase after vasoactive drugs. Br J Haematol 30:81-93.
173. Mannucci PM, Canciani MT, Rota L, Donovan RD (1981): Response of factor VIII/von Willebrand's factor in healthy subjects and patients with haemophilia A and von Willebrand's disease. Br J Haematol 47:283-293.
174. Marciniak E (1973): Factor-Xa inactivation by antithrombin III: evidence for biological stabilization of factor Xa by factor V-phospholipid complex. Br J Haematol 24:391-400.
175. Marder VJ, Budzynski AZ (1974): Degradation products of fibrinogen and crosslinked fibrin: projected clinical applications. Thromb Diath Haemorrh 32:49-56.
176. Marder VJ, Shulman NR (1964): Clinical aspects of congenital Factor VII deficiency. Am J Med 37:182-190.
177. Martin SC, Forsberg P-O, Eriksson SD (1991): The effects of in vitro phosphorylation and dephosphorylation on the thrombin-induced gelation and plasmin degradation of fibrinogen. Thromb Res 61:243-252.
178. McMullen BA, Fujikawa K, Kisiel W, Sasagawa T, Howald WN, Kwa EY, Weinstein B (1983): Complete amino acid sequence of the light chain of human blood coagulation factor VII: evidence for identification of residue 63 as beta-hydroxyaspartic acid. Biochemistry 22:2875-2884.
179. McMullen BA, Fujikawa K, Davie EW (1991): Location of the disulfide bonds in human coagulation Factor XI: the presence of tandem apple domains. Biochemistry 30:2056-2060.
180. McMullen BA, Fujikawa K, Davie EW, Hedner U, Ezban M, (1995): Locations of disulfide bonds and free cysteines in the heavy and light chains of recombinant human factor VIII (antihemophilic factor A). Protein Sci 4:740-746.
181. Michnick DA, Pittman DD, Wise RJ, Kaufman RJ (1994): Identification of individual tyrosine sulfation sites within factor VIII required for optimal activity and efficient thrombin cleavage. J Biol Chem 269:20095-20102.
182. Miletich JP, Majerus DW, Majerus PW (1978a): Patients with congenital factor V deficiency have decreased factor Xa binding sites on their platelets. J Clin Invest 62:824-831.
183. Miletich JP, Jackson CM, Majerus PW (1978b): Properties of the factor Xa binding site on human platelets. J Biol Chem 253:6908-6916.
184. Miletich JP, Kane WH, Hofmann SL, Stanford N, Majerus PW (1979): Deficiency of factor Xa-factor Va binding sites on the platelets of a patient with a rare bleeding disorder. Blood 54:1015-1022.
185. Minnema MC, Friederich PW, Levi M, Meijers JCM, Biemond BJ, Bouma BN, ten Cate H (1997): Inhibition of factor XI activity results in enhanced endogenous thrombolysis in a rabbit thrombosis model. Thromb Hemost Suppl PS-873, 215 (Abstr.).
186. Monkovic DD, Tracy PB (1990a): Activation of human factor V by factor Xa and thrombin. Biochemistry 29:1118-1128.
187. Monkovic DD, Tracy PB (1990b): Functional characterization of human platelet-released factor V and its activation by factor Xa and thrombin. J Biol Chem 265:17132-17140.
188. Morrissey JH, Macik BG, Neuenschwander PF, Comp PC (1993): Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 81:734-744.
189. 2+-AT-Pase: a candidate aminophospholipid translocase. FEBS Lett 266:29-32.
190. Naito K, Fujikawa K (1991): Activation of human blood coagulation factor XI independent of factor XII: factor XI is activated by thrombin and factor XIa in the presence of negatively charged surfaces. J Biol Chem 266:7353-7358.
191. Naglia R, Sinha D, Walsh PN (1989): Functional domains in the heavy-chain region of factor XI: a high molecular weight kininogen-binding site and a substrate-binding site for factor IX. Blood 74:244-251
192. Narita M, Bu G, Olins GM, Higuchi DA, Herz J, Broze GJ, Jr, Schwartz AL, (1995): Two receptor systems are involved in the plasma clearance of tissue factor pathway inhibitor in vivo. J Biol Chem 270:24800-24804.
193. Nawroth PP, Handley DA, Esmon CT, Stern DM (1986): Interleukin 1 induces endothelial cell procoagulant while suppressing cell surface anticoagulant activity. Proc Natl Acad Sci USA 83:3460-3464.
194. Nawroth PP, Stern DM (1986): Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med 163:740-745.
195. Nesheim ME, Wang W, Boffa M, Nagashima M, Morser J, Bajzar L (1997); Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis. Thromb Hemost 78:386-391.
196. Nesheim ME, Foster WB, Hewick R, Mann KG (1984a): Characterization of factor V activation intermediates. J Biol Chem 259:3187-3196
197. Nesheim ME, Tracy RP, Mann KG (1984b): "Clotspeed," a mathematical simulation of the functional properties of prothrombinase. J Biol Chem 259:1447-1453.
198. 35S-Labeled recombinant factor VIII to activated and unactivated human platelets. J Biol Chem 263:16467-16470.
199. Nesheim ME, Mann KG (1983). The kinetics and cofactor dependence of the two cleavages involved in prothrombin activation. J Biol Chem 258:5386-5391.
200. R506Q mutation. Blood 88:1183-1187.
201. Nichols WL, Gastineau D, Solberg L, Mann KG (1985): Identification of human megakaryocyte coagulation factor V. Blood 65:1396-1406.
202. Nilsson IM, Holmberg L, Åberg M, Vilhardt H (1980): The release of plasminogen activator and factor VIII after injection of DDAVP in healthy volunteers and in patients with von Willebrand's disease. Scand J Haematol 24:351-359.
203. Nordvang O, Bjorn SE, Valentin S, Nielsen LS, Wildgoose P, Beck TC, Hedner U (1991): The C-terminus of tissue factor pathway inhibitor is essential to its anticoagulant activity. Biochemistry 30:10371-10376.
204. Novotny WF, Girard TJ, Miletich JP, Broze GJ, Jr. (1989): Purification and characterization of the lipoprotein-associated coagulation inhibitor from human plasma. J Biol Chem 264:18832-18837.
205. Novotny WF, Palmier M, Wun TC, Broze GJ, Jr., Miletich JP (1991): Purification and properties of heparin releasable lipoprotein-associated coagulation inhibitor. Blood 78:394-400.
206. O'Hara PJ, Grant FJ, Haldeman BA (1987): Nucleotide sequence of the gene coding for human factor VII, a vitamin K-dependent protein participating in blood coagulation. Proc Natl Acad Sci USA 84:5158-5162.
207. Olson ST, Bjork I, Shore JD (1993): Kinetic characterization of heparin-catalyzed and uncatalyzed inhibition of blood coagulation proteinases by antithrombin. In: Lorand L, Mann KG (eds.): "Methods in Enzymology Part A." San Diego: Academic Press, pp. 525-559.
208. Olson ST, Shore JD (1982): Demonstration of a two step reaction mechanism for inhibition of α-thrombin by antithrombin III and identification of the step affected by heparin. J Biol Chem 257:14891-14895.
209. Østerud B, Rapaport S I (1977): Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation. Proc Natl Acad Sci USA 74:5260-5264.
210. Østerud B, Rapaport SI (1970): Synthesis of intrinsic factor X activator. Inhibition of the function of formed activator by antibodies to factor VIII and to factor IX. Biochemistry 9:1854-1861.
211. Østerud B, and Flægstad T (1983): Increased tissue thromboplastin activity in monocytes of patient with meningococcal infection: related to an unfavorable prognosis. Thromb Hemost 49:5-7.
212. 2+ concentration. Biochemistry 34:9277-9281.
213. Owen WG, Esmon CT (1981): Functional properties of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. J Biol Chem 256:5532-5535.
214. Owren PA (1947): Parahaemophila: haemorrhagic diathesis due to absence of a previously unknown clotting factor. Lancet 1993:446-448.
215. Owren PA, Cooper T (1955): Parahemophilia. Arch Intern Med 95:194-201.
216. Park CT, Creasey AA, Wright SD (1997): Tissue factor pathway inhibitor blocks cellular effects of endotoxin by binding to endotoxin and interfering with transfer to CD14. Blood 89:4268-4274.
217. 32P]ATP. FEBS Lett 143:199-204.
218. Petäjä J, Fernandez JA, Gruber A, Griffin JH (1997): Anticoagulant synergism of heparin and activated protein C in vitro: role of a novel anticoagulant mechanism of heparin, enhancement of inactivation of factor V by activated protein C. J Clin Invest 99:2655-2663.
219. Pieters J, Lindhout T, Hemker HC (1989): In situ generated thrombin is the only enzyme that effectively activates factor VIII and factor V in thromboplastin-activated plasma. Blood 74:1021-1024.
220. Picketts DJ, Mueller CR, Lillicrap D (1994): Transcriptional control of the factor IX gene: analysis of five cis-acting elements and the deleterious effects of naturally occurring hemophilia B Leyden mutations. Blood 84:2992-3000.
221. Pittman DD, Tomkinson KN, Kaufman RJ (1994a): Posttranslational requirement for functional factor V and factor VIII secretion in mammalian cells. J Biol Chem 269:17329-17337.
222. Pittman DD, Tomkinson KN, Michnick D, Selighsohn U, Kaufman RJ (1994b): Posttranslational sulfation of factor V is required for efficient thrombin cleavage and activation and for full procoagulant activity. Biochemistry 33:6952-6959.
223. Prendergast FG, Mann KG (1977): Differentiation of metal ion induced transitions of prothrombin fragment 1. J Biol Chem 252:840-850.
224. Proudfoot NJ, Brownlee GG, (1976): 3′ noncoding region sequences in eukaryotic messenger RNA. Nature 263:211-214.
225. Radcliffe R, Nemerson Y (1975): Activation and control of factor VII by activated factor X and thrombin. J Biol Chem 250:388-395.
226. Rand MD, Kalafatis M, Mann KG (1994): Platelet coagulation factor Va: the major secretory platelet phosphoprotein. Blood 83:2180-2190.
227. Rao LVM, Rapaport SI, Hoang AD (1993): Binding of factor VIIa to tissue factor permits rapid antithrombin III/Heparin inhibition of factor VIIa. Blood 81:2600-2607.
228. Rapaport SI (1989): Inhibition of factor VIIa/tissue factor-induced blood coagulation: with particular emphasis upon a factor Xa-dependent inhibitory mechanism. Blood 73:359-365.
229. Rapaport SI, Rao LVM (1995): The tissue factor pathway: how it has become a 'prima ballerina'. Thromb Haemostasis 74:7-17.
230. Rapaport SI, Proctor RR, Patch MJ, Yettra M (1961): The mode of inheritance of PTA deficiency: evidence for the existence of major PTA deficiency and minor PTA deficiency. Blood 18:149-165.
231. Rapaport SI, Rao LVM (1992): Initiation and regulation of tissue factor dependent blood coagulation. Arterioscl Thromb 12:1111-1121.
232. Ratnoff OD, Colopy JE (1955): A familial hemorrhagic trait associated with a deficiency of a clot-promoting fraction of plasma. J Clin Invest 34:602-613.
233. Repke D, Gemmel CH, Guha A, Turrito VT, Broze GJ, Jr, Nemerson Y (1990): Hemophilia as a defect of the tissue-factor pathway of blood coagulation: effect of factors VIII and IX on factor X activation in a continuous-flow reactor. Proc Natl Acad Sci USA 87:7623-7627.
234. Robinson RA, Worfolk L, Tracy PB (1992): Endotoxin enhances the expression of monocyte prothrombinase activity. Blood 79:406-416.
235. Rodgers GM, Shuman MA (1983): Prothrombin is activated on vascular endothelial cells by factor Xa and calcium. Proc Natl Acad Sci USA 80:7001-7005.
236. Rosenthal RL, Dreskin OH, Rosenthal N (1953): New hemophilia-like disease caused by deficiency of a third plasma thromboplastin factor. Proc Soc Exp Biol Med 82:171-174.
237. Rosing J, VanRijn JLML, Bevers EM, VanDiejen G, Comfurius P, Zwaal RFA (1985): The role of activated human platelets in prothrombin and factor X activation. Blood 65:319-322.
238. R506Q by activated protein C. J Biol Chem 270:27852-27858.
239. Royle NJ, Fung MR, MacGillivray RTA, Hamerton JL (1986): The gene for clotting factor X is mapped to 13q32:qter. Cytogenet Cell Genet 41:185-188.
240. Saito H, Ratnoff OD, Waldmann R, and Abraham JP (1975): Fitzgerald trait. Deficiency of a hitherto unrecognized reagent, Fitzgerald factor, participating in surface mediated reactions of clotting, fibrinolysis, generation of kinins, and the property of diluted plasma enhancing vascular permeability. J Clin Invest 55:1082-1089.
241. Sandset PM, Abildgaard U, Larsen ML (1988): Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res 50:803-813.
242. Sandset PM, Warn-Cramer BJ, Rao RTA, Maki SL, Rapaport SI (1991): Depletion of extrinsic pathway inhibitor (EPI) sensitizes rabbits to disseminated intravascular coagulation induced with tissue factor: evidence supporting a physiologic role for EPI as a natural anticoagulant. Proc Natl Acad Sci USA 88:708-712.
243. Scarpati EM, Wen D, Broze GA (1987): Human tissue factor: cDNA sequence and chromosome localization of the gene. Biochemistry 26:5234-5238.
244. Scharfstein J, Ferreira A, Gigli I, Nussenzweig V (1978): Human C4b-binding protein. I. Isolation and characterization. J Exp Med 148:207-222.
245. Scheraga HA, Laskowski M, Jr (1957): The fibrinogen-fibrin conversion. Adv Protein Chem 12:1-5.
246. Schmidel DK, Tatro AV, Phelps LG, Tomczak JA, Long GL (1990): Organization of the human protein S genes. Biochemistry 29:7845-7852.
247. Scott CF, Colman RF (1992): Fibrinogen blocks the autoactivation and thrombin-mediated activation of factor XI on dextran sulfate. Proc Natl Acad Sci USA 89:11189-11193.
248. Seigneuret M, Devaux PF (1984): Asymmetric distribution of spin-labeled phospholipids in the erythrocyte membrane: relation to shape changes. Proc Natl Acad Sci USA 81:3751-3755.
249. Seligsohn U, Osterud G, Brown SF, Griffin JH, Rappaport SI (1979): Activation of human factor VII in plasma and in purified systems: roles of activated factor IX, kallikrein and activated factor XII. J Clin Invest 64:1056-1065.
250. Silverberg SA, Nemerson Y, Zur M (1977): Kinetics of the activation of bovine coagulation factor X by components of the extrinsic pathway: kinetic behavior of two-chain factor VII in the presence and absence of tissue factor. J Biol Chem 252:8481-8488.
251. Sixma JJ, van den Berg A (1984): The haemostatic plug in haemophilia A: a morphological study of haemostatic plug formation in bleeding time skin wounds of patients with severe haemophilia A. Br J Haematol 58:741-753.
252. Solymoss S, Tucker MM, Tracy PB (1988): Kinetics of inactivation of membrane-bound factor Va by activated protein C. Protein S modulates factor Xa protection. J Biol Chem 263:14884-14890.
253. 2+ prothrombin fragment 1 including the conformation of the Gla domain. Biochemistry 28:6805-6810.
254. 2+ ion and membrane binding structure of the Gla domain of Ca-prothrombin fragment 1. Biochemistry 31:2554-2566.
255. Stern DM, Nawroth PP, Kisiel W, Handley D, Drillings M, Bartos J (1984): A coagulation pathway on bovine aortic segments leading to the generation of factor Xa and thrombin. J Clin Invest 74:1910-1921.
256. Stern DM, Nawroth PP, Handley D, Kisiel W (1985): An endothelial cell dependent pathway of coagulation. Proc Natl Acad Sci USA 82:2523-2527.
257. Sune A, Bette-Bobillo P, Bienvenue A, Fellman, P, Devaux PF (1987): Selective outside-inside translocation of aminophospholipids in human platelets. Biochemistry 26:2972-2978.
258. Suzuki K, Dahlbäck B, Stenflo J (1982): Thrombin-catalyzed activation of human coagulation Factor V. J Biol Chem 257:6556-6564.
259. Suzuki K, Kusumoto H, Deyashiki Y, Nishioka J, Maruyama I, Zushi M, Kawahara S, Honda G, Yamamoto S, Horiguchi S (1987): Structure and expression if human thrombomodulin, a thrombin receptor on endothelium acting as a cofactor for protein C activaton. EMBO J 6:1891-1897.
260. Tavenner RW (1968): Epsilon-aminocaproic acid in the treatment of haemophilia and Christmas disease with special reference to the extraction of teeth. Br Dental J 124:19-22.
261. Tilly RHJ, Senden JMG, Comfurius P, Bevers EM, Zwaal, RFA (1990): Increased aminophospholipid translocase activity in human platelets during secretion. Biochim Biophys Acta 1029:188-190.
262. Thompson AR (1986): Structure, function, and molecular defects of factor IX. Blood 67:565-572.
263. Toole JJ, Knopf JL, Wozney JM, Sultman LA, Buecker JL, Pittman DD, Kaufman RJ, Brown E, Shoemaker C, Orr EC, Amphlett GW, Foster WB, Coe ML, Knutson GJ, Fass DN, Hewick RM (1984): Molecular cloning of a cDNA encoding human antihaemophilic factor. Nature 312:342-347.
264. Toti F, Satta N, Fressinaud E, Meyer D, Freyssinet JM (1996): Scott syndrome, characterized by impaired transmembrane migation of procoagulant phosphatidylserine and hemorrhagic complications, is an inherited disorder. Blood 87:1409-1415.
265. Tracy PB, Rohrbach MS, Mann, KG (1983): Functional prothrombinase complex assembly on isolated monocytes and lymphocytes. J Biol Chem 258:7264-7267.
266. Tracy PB, Eide LL, Mann, KG (1985): Human prothrombinase complex assembly on isolated peripheral blood cell populations. J Biol Chem 258:7264-7267.
267. Tracy PB (1988): Regulation of thrombin generation at cell surfaces. Semin Hemost Thromb 14:227-233
268. Tracy PB, Peterson JM, Nesheim ME, McDuffie FC, Mann KG (1979): Interaction of coagulation factor V and factor Va with platelets. J Biol Chem 254:10354-10361.
269. Tracy PB, Nesheim ME, Mann KG (1981): Coordinate binding of factor Va and factor Xa to the unstimulated platelet. J Biol Chem 256:743-751.
270. Tracy PB, Eide LL, Bowie EJW, Mann KG (1982): Radioimmunoassay of factor V in human plasma and platelets. Blood 60:59-63.
271. Tracy PB, Mann KG (1983): Prothrombinase complex assembly on the platelet surface is mediated through the 74,000-dalton component of factor Va. Proc Natl Acad Sci USA 80:2380-2384.
272. Tsay W, Lee YM, Lee SC, Shen MC, Chen PJ (1996): Characterization of human protein C gene promoter: insights from natural human mutants. DNA Cell Biol 15:907-919.
273. Tsiang M, Lentz SR, Sadler JE (1992): Functional domains of membrane-bound human thrombomodulin. EGF-like domains four to six and the serine/threonine-rich domain are required for cofactor activity. J Biol Chem 267:6164-6170.
274. Tuddenham EGD, Schwaab R, Seehafer J, Millar DS, Gitschier J, Higuchi M, Bidichandani S, Connor JM, Hoyer LW, Yoshioka A, Peake IR, Olek K, Kazazian HH, Lavergne JM, Giannelli F, Antonarakis SE, Cooper DN (1994); Haemophillia A: database of nucleotide substitutions, deletions, insertions, rearrangements of the factor VIII gene, second edition. Nucl Acids Res 22:4851-4868.
275. Tulinsky A, Park CH, Rydel TJ (1985): The structure of prothrombin fragment 1 at 3.5 Å resolution. J Biol Chem 260:10771-10778.
276. Tulinsky A, Park CH, Skrzypczak-Jankun E (1988): Structure of prothrombin fragment 1 refined at 2.8 À resolution. Biochemistry 28:6805-6810.
277. van 't Veer C, Hacckeng TM, Biesbroeck D, Sixma JJ, Bouma BN (1995): Increased prothrombin activation in protein S-deficient plasma under flow conditions on endothelial cell matrix: an independent anticoagulant function of protein S in plasma. Blood 85:1815-1821.
278. van 't Veer C, Golden NJ, Kalafatis M, Mann KG (1997a): Inhibitory mechanism of the protein C pathway on tissue factor-induced thrombin generation. J Biol 272:7983-7994.
279. van 't Veer C, Golden NJ, Mann KG (1997b): Regulation of prothrombinase activity by protein S. Thromb Haemost 77:755 (Abstr.).
280. LEIDEN. Blood (in press).
281. van 't Veer C, Mann KG (1997): Regulation of tissue factor initiated thrombin generation by the stoichiometric inhibitors tissue factor pathway inhibitor, antithrombin-III, and heparin cofactor-II. J Biol Chem 272:4367-4377.
282. van Wijnem M, Stam JG, van 't Veer C, Meijers JC, Reitsma PH, Bertina RM, Bouma BN (1996): The interaction of protein S with the phospholipid surface is essential for the activated protein C-independent activity of protein S. Thromb Haemost 76:397-403.
283. van Wijnen M, van 't Veer C, Meijers JCM, Bertina RM, Nouma BN (1997): A plasma coagulation assay to determine the activated protein C independent anticoagulant activity of protein S. Thromb Haemost 77:756 (Abstr.).
284. Vehar G, Keyt B, Eaton D, Rodriguez H, O'Brien DP, Rotblat F, Oppermann H, keck R, Wood W, Harkins R, Tuddenham EGD, Lawn R, Capon D (1984): Structure of human factor VIII. Nature 312:337-342.
285. Vehar G, Davie E, (1980): Preparation and properties of bovine FVIII (anit-hemophilic factor). Biochemistry 19:401-410.
286. von dem Borne, PA Kr, Meijers JCM, Bouma BN (1995): Feedback activation of factor XI by thrombin in plasma results in additional thrombin that protects fibrin clots from fibrinolysis. Blood 86:3035-3042.
287. von dem Borne PA Kr, Meijers JCM, Seligsohn U, Bouma BN (1997): Variable potential of the intrinsic coagulation pathway for inhibition of plasma clot lysis in normal and factor XI deficient individuals. Thromb Hemost Supplement PS-858, 212 (Abstr.).
288. von dem Borne PA Kr, Koppelman SJ, Bouma BN, Meijers JCM (1994): Surface independent factor XI activation by thrombin in the presence of high molecular weight kininogen. Thromb Haemost 72:397-402.
289. Waldmann R, Abraham JP, Rebuck JW, Caldwell J, Saito H, Ratnoff OD (1974): Fitzgerald factor: a hitherto unrecognized coagulation factor. Lancet 1:949-952.
290. Walker FJ, (1980): Regulation of activated protein C by a new protein: a possible function for bovine protein S. J Biol Chem 255:5521-5524.
291. Walker FJ, (1981): Regulation of activated protein C by protein S. J Biol Chem 256:11128-11131.
292. Walsh PN, Rizza CR, Matthews JM, Eipe J, Kernoff PBA, Coles MD, Bloom AL, Kaufman BM, Beck P, Hanan CM, Biggs R (1971): Epsilon-aminocaproic acid therapy for dental extractions in haemophilia and Christmas disease: a double blind controlled trial. Br J Haematol 20:463-475.
293. Walsh PN, Baglia FA, Jameson BA (1993): Factor XI: structure-function relationships utilizing monoclonal antibodies, protein modification, computational chemistry, and rational synthetic peptide design. In: Lorand L, Mann KG (eds.): "Methods in Enzymology Part A." San Diego: Academic Press, pp. 65-96.
294. Walsh, P.N. (1992): Factor XI: a renaissance. Semin Hematol 29:189-201.
295. Wang W, Boffa MB, Walker J, Nesheim ME (1996): A study of the mechanism of inhibition of t-PA mediated fibrinolysis by activated TAFI. Fibrinolysis 10:278:82 (Abstr.).
296. Warn-Cramer BJ, Rapaport SI (1993): Studies of factor Xa/ phospholipid-induced intravascular coagulation in rabbits. Effects of immunodepletion of tissue factor pathway inhibitor. Arterioscler Thromb 13:1551-1622.
297. Weiss HJ, Vivic WJ, Lages BA, Rogers J (1979): Isolated deficiency of platelet procoagulant activity. Am J Med 67:206-213.
298. Weiss HJ (1994): Scott syndrome: a disorder of platelet coagulant activity. Semin Hematol 31:312-319.
299. Weller-Guettler H, Yu K, Soff G, Gudas LJ, Rosenberg RD (1992): Thrombomodulin gene regulation by cAMP and retinoic acid in F9 embryonal carcinoma cells. Proc Natl Acad Sci USA 89:2155-2159.
300. Wen D, Dittman WA, Ye RD, Deaven LL, Majerus PW, Sadler JE (1987): Human thrombomodulin: complete cDNA sequence and chromosome localization of the gene. Biochem 26:4350-4357.
301. Wesselschmidt RL, Girard TJ, Likert KM, Wun T, Broze GJ, Jr (1992): Tissue factor pathway inhibitor: the carboxyterminus is required for optimal inhibition of factor Xa. Blood 79:2004-2010.
302. Wilson DB, Salem HH, Mruk JS, Maruyama I, Majerus PW (1984): Biosynthesis of coagulation factor V by a human hepatocellular carcinoma cell line. J Clin Invest 73:654-658.
303. Wilson MJ, Richterlowney K, Daleke DL (1993): Hyperglycemia induces a loss of phospholipid asymmetry in human erythrocytes. Biochemistry 32:11302-11310.
304. Williamson P, Bevers EM, Smeets EF, Comfurius P, Schlegel RA, Zwaal RFA (1995): Continuous analysis of the mechanism of activated transbilayer movement lipid movement in platelets. Biochemistry 34:10448-10455.
305. Wion KL, Kelly D, Summerfield JA, Tuddenham EG, Lawn RM (1985): Distribution of factor VIII mRNA and antigen in human liver and other tissues. Nature 317:726-729.
306. Wolfenstein-Todel C, Mosesson MW (1981): Carboxy-terminal amino acid sequence of a human fibrinogen γ-chain variant (γ′). Biochemistry 20:6146-6149.
307. Wuepper KD (1973): Prekallikrein deficiency in man. J Exp Med 138:1345-1355.
308. Wuepper KD, Miller DR, Lacombe MJ (1975): Flaujeac trait. Defiency of human plasma kininogen. J Clin Invest 56:1663-1672.
309. Xue J, Kalafatis M, Mann KG (1993): Determination of the disulfide bridges in factor Va light chain. Biochemistry 32:5917-5923.
310. Xue J, Kalafatis M, Silveira JR, Kung C, Mann KG (1994): Determination of the disulfide bridges in factor Va heavy chain. Biochemistry 33:13109-13116.
311. Yoshitake S, Schach BG, Foster DC, 1985. Nucleotide sequence of the gene for human factor IX (Antihemophilic factor B). Biochemistry 24:3736
312. Zimmerman ML, Daleke DL (1993): Regulation of a candidate aminophospholipid-transporting ATPase by lipid. Biochemistry 32:12257-12263.
313. Zionchech TF, Roy S, Vehar GA (1992): The cytoplasmic domain of tissue factor is phosphorylated by a protein kinase C-dependent mechanism. J Biol Chem 267:3561-3564.
314. Zöller B, Garcia de Frutos P, Dahlbäck B (1995): Evaluation of the relationship between protein S and C4b-binding protein isoforms in hereditairy protein S deficiency demonstrating type I and type III deficiencies to be phenotypic variants of the same genetic disease. Blood 85:3524-3531.
315. Zöller B, Hillarp A, Berntorp E, Dahlbäck B (1997): Activated protein C resistance due to a common factor V gene mutaion is a major risk factor for venous thrombosis. Annu Rev Med 48:45-58.
316. m, on tissue factor. J Biol Chem 255:5703-5707.
317. Zwaal RFA, Bevers EM, Comfurius P, Rosing J, Tilly RHJ, Verhallen PFJ (1989): Loss of membrane phospholipid assymetry during activation of blood platelets and sickled red cells. Mechanisms and physiological significance. Mol Cell Biochem 91:23-31.